Pharmaceutical Raw Material CAS 486460-32-6 Lipid-Regulating Drugs Sitagliptin

Product Details
Customization: Available
Powder: Yes
Customized: Non-Customized
Still deciding? Get samples of US$ 520/kg
Request Sample
Diamond Member Since 2021

Suppliers with verified business licenses

Audited Supplier

Audited by an independent third-party inspection agency

Registered Capital
10000000 RMB
Plant Area
101~500 square meters
  • Pharmaceutical Raw Material CAS 486460-32-6 Lipid-Regulating Drugs Sitagliptin
  • Pharmaceutical Raw Material CAS 486460-32-6 Lipid-Regulating Drugs Sitagliptin
  • Pharmaceutical Raw Material CAS 486460-32-6 Lipid-Regulating Drugs Sitagliptin
  • Pharmaceutical Raw Material CAS 486460-32-6 Lipid-Regulating Drugs Sitagliptin
  • Pharmaceutical Raw Material CAS 486460-32-6 Lipid-Regulating Drugs Sitagliptin
  • Pharmaceutical Raw Material CAS 486460-32-6 Lipid-Regulating Drugs Sitagliptin
Find Similar Products

Basic Info.

Model NO.
HNB-240
Certification
GMP, HSE, ISO 9001, USP, BP
Suitable for
Elderly, Children, Adult
State
Powder
Purity
>99%
Transport Package
Aluminium Foil Bag, Cardboard Drum
Trademark
HNB-Biotech
Origin
Shaanxi, China
Production Capacity
5000kg/Month

Product Description

Pharmaceutical Raw Material CAS 486460-32-6 Lipid-regulating Drugs Sitagliptin
Pharmaceutical Raw Material CAS 486460-32-6 Lipid-Regulating Drugs Sitagliptin
Pharmaceutical Raw Material CAS 486460-32-6 Lipid-Regulating Drugs Sitagliptin
Product name Sitagliptin
Cas No. 486460-32-6
Molecular Formula C16H15F6N5O
Appearance White powder


Sitagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that controls blood glucose levels by protecting and enhancing endogenous enteroglycin.Glucose-dependent insulin-releasing peptides (GIP) and glucagon-like peptide-1 (GLP-1) are enteroglycins released in response to dietary intake.

GLP-1 and GIP can increase insulin synthesis and release from islet β cells through intracellular signaling pathways. GLP-1 can also reduce glucagon secretion from islet α cells and reduce hepatic glucose production.However, both GLP-1 and GIP are rapidly metabolized by DPP-4, resulting in the loss of their insulin-promoting effect.

Pharmaceutical Raw Material CAS 486460-32-6 Lipid-Regulating Drugs SitagliptinPharmaceutical Raw Material CAS 486460-32-6 Lipid-Regulating Drugs SitagliptinPharmaceutical Raw Material CAS 486460-32-6 Lipid-Regulating Drugs SitagliptinPharmaceutical Raw Material CAS 486460-32-6 Lipid-Regulating Drugs SitagliptinPharmaceutical Raw Material CAS 486460-32-6 Lipid-Regulating Drugs SitagliptinPharmaceutical Raw Material CAS 486460-32-6 Lipid-Regulating Drugs SitagliptinPharmaceutical Raw Material CAS 486460-32-6 Lipid-Regulating Drugs Sitagliptin
 

Send your message to this supplier

*From:
*To:
*Message:

Enter between 20 to 4,000 characters.

This is not what you are looking for? Post a Sourcing Request Now
Contact Supplier